Expertise
Mr. Batchelder is a Venture Partner at Pivotal BioVentures and a life science industry veteran with more than two decades of experience helping shape the strategies of companies and organizations involved in the development of groundbreaking therapeutics.
Mr. Batchelder is currently the Executive Chair for XyloCor Therapeutics and serves on the boards of OncXerna Therapeutics and The Michael J. Fox Foundation for Parkinson’s Research.
Background
Previously he was cofounder and chief executive officer of Civitas Therapeutics, a pulmonary delivery company with a lead program for treating Parkinson’s disease that was acquired by Acorda Therapeutics. Acorda subsequently launched INBRIJA®, the inhaled therapy to treat Parkinson’s OFF episodes which had been Civitas’ lead program. Prior to his work with Civitas, Mr. Batchelder was the founding CEO of BIND Therapeutics (BIND), a nanotherapeutics oncology company that was acquired by Pfizer. Before BIND, he was the initial CEO of Acceleron Pharma (XLRN), a biotherapeutics company focused in the TGF-beta superfamily signaling space and hematology that was acquired by Merck. Mr. Batchelder also served as senior vice president of operations at Millennium Pharmaceuticals where his responsibilities included a leadership role in support of the VELCADE® launch for multiple myeloma and was responsible for the commercial supply chain and technical operations for INTEGRLIN®.
He is also a former Chair of MassBio’s Board of Directors. Mr. Batchelder received a BS in chemical engineering from Lehigh University.
